Experts emphasize the need to continue to focus on healthy dietary and lifestyle practices
MONDAY, Jan. 12, 2026 (HealthDay News) — Cessation of weight management medications (WMMs) is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers, according to a review published online Jan. 7 in The BMJ.
Sam West, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a systematic literature review to quantify and compare the rate of weight regain after cessation of WMMs in adults with overweight or obesity.
Based on 37 included studies (9,341 participants), the average monthly rate of weight regain was 0.4 kg (mixed model, 0.3 kg monthly versus control in randomized controlled trials) during an average treatment duration of 39 weeks and an average follow-up of 32 weeks. Within 1.4 years after the cessation of WMMs, all cardiometabolic markers were projected to return to baseline. Compared with cessation of behavioral weight management programs, weight regain was faster after cessation of WMMs (by 0.3 kg monthly), independent of initial weight loss.
“GLP-1 receptor agonists should not be relied on as a magic cure for treating obesity,” Qi Sun, M.D., from Brigham and Women’s Hospital in Boston, writes in an accompanying editorial. “Healthy dietary and lifestyle practices should remain the foundation for obesity treatment and management, with medications such as GLP-1 receptor agonists used as adjuncts.”
Three authors disclosed ties to the Novo Nordisk Foundation.
Calorie Restriction and Mediterranean-Style Diet Yield Similar Weight Loss
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout